NCT07085091View on ClinicalTrials.gov

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)HNSCCCRC (Colorectal Cancer)ESCCColo-rectal CancerHead and Neck CancerEsophageal Squamous Cell Carcinoma (ESCC)
Interventions
DRUG

ALX2004

ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV Infusion

DRUG

ALX2004

ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV infusion

DRUG

ALX2004

ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV infusion

Trial Locations (4)

22031

RECRUITING

NEXT Oncology, Fairfax

49546

RECRUITING

START Midwest, Grand Rapids

84119

RECRUITING

START Mountain Region, West Valley City

99208

RECRUITING

Summit Cancer Center, Spokane

Sponsors

Lead Sponsor

ALX Oncology Inc.
All Listed Sponsors
lead

ALX Oncology Inc.

INDUSTRY